鲁索利替尼在日本骨髓纤维化患者中的长期安全性和有效性:一项观察性研究。

IF 2.6 4区 医学 Q2 ONCOLOGY
Future oncology Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI:10.1080/14796694.2025.2550924
Yusuke Aruga, Wataru Hongo, Weizhe Lu
{"title":"鲁索利替尼在日本骨髓纤维化患者中的长期安全性和有效性:一项观察性研究。","authors":"Yusuke Aruga, Wataru Hongo, Weizhe Lu","doi":"10.1080/14796694.2025.2550924","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan.</p><p><strong>Methods: </strong>A multicenter, observational study of patients who received ruxolitinib for MF from July 2014.</p><p><strong>Results: </strong>Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached.</p><p><strong>Conclusion: </strong>In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3017-3026"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490404/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.\",\"authors\":\"Yusuke Aruga, Wataru Hongo, Weizhe Lu\",\"doi\":\"10.1080/14796694.2025.2550924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan.</p><p><strong>Methods: </strong>A multicenter, observational study of patients who received ruxolitinib for MF from July 2014.</p><p><strong>Results: </strong>Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached.</p><p><strong>Conclusion: </strong>In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"3017-3026\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490404/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2550924\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2550924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价鲁索利替尼治疗日本骨髓纤维化(MF)患者的安全性和有效性。方法:对2014年7月开始接受鲁索利替尼治疗MF的患者进行多中心观察性研究。结果:892例患者(平均年龄70岁,45.9%原发MF,鲁索利替尼治疗中位持续时间541.0天)中,67.7%发生药物不良反应(adr), 31.5%发生严重adr。最常见的不良反应是贫血和血小板计数减少。从治疗开始至第182天,以及此后每6个月至第1093天及以后,按发病时间划分的不良反应发生率分别为57.7%、20.3%、14.4%、11.1%、11.3%、9.0%和1.8%。特别关注的不良反应包括骨髓抑制(46.8%)、感染(17.6%)、肝功能损害(13.5%)、出血性事件(10.2%)、心力衰竭(2.5%)、间质性肺疾病(1.5%)、恶性肿瘤(1.4%)和结核病(0.5%)。常见不良反应的发生率在肝肾损害患者和无肝肾损害患者之间相似。6个月时,26.2%的患者脾脏得到缓解,52.0%的患者症状得到改善。中位总生存期未达到。结论:在日本的现实环境中,ruxolitinib显示出合理程度的有效性,没有新的安全性问题。结果与临床试验结果相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.

Aim: To evaluate the safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF) in Japan.

Methods: A multicenter, observational study of patients who received ruxolitinib for MF from July 2014.

Results: Of 892 patients (mean age: 70 years, 45.9% primary MF, ruxolitinib treatment median duration, 541.0 days), 67.7% had adverse drug reactions (ADRs) and 31.5% had serious ADRs. The most frequent ADRs were anemia and decreased platelet count. Incidences of ADRs by time of onset were 57.7%, 20.3%, 14.4%, 11.1%, 11.3%, 9.0%, and 1.8% from the treatment initiation to Day 182, and every 6 months thereafter until Day 1,093 or later, respectively. ADRs of special interest included myelosuppression (46.8%), infections (17.6%), hepatic impairment (13.5%), hemorrhagic events (10.2%), cardiac failure (2.5%), interstitial lung disease (1.5%), malignancy (1.4%) and tuberculosis (0.5%). Incidences of common ADRs were similar between patients with hepatic or renal impairment and patients without hepatic or renal impairment. At 6 months, spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival was not reached.

Conclusion: In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信